Across TCGA pan-cancer cohorts, SLC34A3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC34A3 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC34A3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC34A3 expression acts as an unfavorable survival marker.

LUAD, LIHC, and LUSC are the cancer types where SLC34A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.278	0.793	<.001	27	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	9	view →
LUSC	OS	Median	II,III,IV	0.173	0.677	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SLC34A3 tumor-vs-normal RNA expression · all SLC34A3 data types